HIV/AIDS therapeutics market led by Gilead as the greatest revenue shareholder

The HIV/AIDS therapeutics market has been forecast to increase at a compound annual growth rate (CAGR) of 7% over the next six years, increasing from a valuation of $13.5 billion in 2011, to hit a market value of $21.8 billion by 2018.

HIV endemic has had devastating economic, social, health and psychological impacts over the years affecting millions of households in a significant manner over the last decade. Despite the concrete efforts from authorities and various philanthropic institutions, the numbers are still on an upward trend with a total of 33.3 million HIV victims across the world recorded in 2009.

As a consequence of the on-going patent-cliff, the predicted growth rate is less than the market has experienced in previous years. Between 2004 and 2011, the market witnessed a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva (efavirenz) and Reyataz (atazanavir) - both produced by Bristol-Myers Squibb - in 2014 and 2017 respectively, a more modest increase is predicted.

However, the HIV/AIDS therapeutics market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.

Last year's sales figures show Gilead as being the greatest revenue shareholder of the world's top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment.

For more information on the HIV/AIDS therapeutics market, see the latest research: HIV/AIDS Therapeutics Market

Follow us on Twitter @CandMResearch